Danaher Corporation Announces Acquisition of Abcam Plc in a $5.7 Billion Deal
Cambridge, England – In an exciting development for the life-sciences industry, Danaher Corporation, a global science and technology innovator, has announced its plans to acquire UK-based Abcam Plc. The deal, valued at $5.7 billion, positions Danaher as the frontrunner in securing the renowned maker of supplies for researchers worldwide.
Danaher’s acquisition of Abcam demonstrates a strategic move to enhance its presence in the life-sciences sector. Abcam, with its cutting-edge technologies and extensive range of products, has established itself as a leader in providing research tools to scientists. This acquisition will provide Danaher with a significant advantage by expanding its portfolio of solutions, ultimately benefiting researchers globally.
According to a statement released on Monday, Danaher will acquire Abcam at a price of $24 per share. The deal, expected to be completed by mid-2024, will include both debt and acquired cash. The corporation plans to fund the transaction through a combination of existing cash reserves and debt.
Commenting on the acquisition, Danaher CEO stated, “We are thrilled to announce our agreement with Abcam, a company that shares our commitment to innovation and making a positive impact on human health. This acquisition aligns with Danaher’s strategy of investing in high-growth markets and bolsters our position as a leading provider of research tools for scientists worldwide.”
Abcam’s CEO, in response to the deal, expressed equal enthusiasm, stating, “Joining forces with Danaher will allow us to drive even greater advancements in scientific research. We are excited about the opportunities that this partnership will bring for our customers and employees alike.”
The merger of Danaher and Abcam will undoubtedly create exciting possibilities for advancements in scientific research. The combined expertise and resources of these two influential companies are expected to greatly impact the life-sciences industry, driving innovation and enabling further breakthroughs in biomedical research.
As the acquisition progresses towards completion, researchers and industry experts eagerly await the synergies that will emerge from this monumental collaboration. With the deal set to close in the near future, the global scientific community awaits the positive implications this development will have on advancing human health and scientific knowledge.
About Danaher Corporation:
Danaher Corporation is a global science and technology innovator committed to providing solutions to address complex challenges in various industries, including life sciences, diagnostics, and environmental and applied solutions. With a diverse portfolio of premier brands, Danaher is dedicated to improving the quality of life around the world.
About Abcam Plc:
Abcam Plc is a leading provider of life science research tools, specializing in the development, manufacturing, and distribution of high-quality antibodies, proteins, and other reagents. Collaborating with scientists worldwide, Abcam’s goal is to support researchers in their efforts to understand and combat human diseases.